Non-Viral Nanocarrier Design for Crossing the Blood–Brain Barrier: From Surface Chemistry to Zeta Potential

Delivering genetic material across the blood–brain barrier (BBB) presents one of the most persistent challenges in central nervous system research. The BBB is highly selective, preventing most macromolecules, including DNA and RNA-based therapeutics, from entering the brain parenchyma. While viral vectors like AAVs have demonstrated some success, non-viral nanocarriers have gained increasing interest due to their lower immunogenicity, flexible payload capacity, and tunable surface properties. Designing these carriers to effectively cross the BBB requires precise manipulation of their physicochemical characteristics, particularly size, surface chemistry, charge, and shape.

One critical parameter is particle size. Nanoparticles between 10 and 100 nanometers tend to exhibit optimal circulation time and biodistribution. Smaller particles may be cleared too quickly, while larger ones are often sequestered by the mononuclear phagocyte system. Shape also plays a role—rod-like or flexible structures have been shown to exhibit different interactions with endothelial cells compared to spherical particles, potentially affecting their ability to undergo transcytosis. Among all features, surface chemistry is arguably the most pivotal. PEGylation, for instance, can reduce protein adsorption and increase circulation time, but excessive PEG density may hinder cellular uptake. Meanwhile, surface functionalization with ligands such as transferrin, angiopep-2, or apolipoproteins can facilitate receptor-mediated transcytosis across the endothelial layer of the BBB.

Zeta potential, a measure of surface charge, determines both colloidal stability and interaction with the cell membrane. Cationic particles tend to interact more strongly with the negatively charged endothelial glycocalyx, promoting endocytosis. However, high positive charge also increases the risk of cytotoxicity and nonspecific binding. Balancing zeta potential with targeting ligand density is thus crucial for maintaining both safety and specificity. Researchers are increasingly developing pH-sensitive or redox-responsive surface coatings that activate only in the brain microenvironment, allowing for a high degree of spatial and temporal control over payload release.

The core composition of the nanocarrier—whether lipid-based, polymeric, or inorganic—also affects BBB penetration. Lipid nanoparticles (LNPs), for instance, mimic endogenous lipoproteins and can be absorbed by endothelial cells via natural transport pathways. Polymeric systems like PLGA or PEI can be engineered for sustained release and charge modulation. Some hybrid systems combine the membrane fusion ability of lipids with the structural stability of polymers to achieve synergistic performance. Furthermore, recent advances in microfluidics and self-assembly methods have enabled the production of nanocarriers with highly uniform sizes and surface architectures, enhancing reproducibility and clinical relevance.

In the context of brain transfection, these nanocarriers offer a promising alternative to viral delivery, especially for transient gene expression or RNA interference applications. The ability to deliver nucleic acids non-invasively, or through minimally invasive methods like intranasal administration, opens the door to repeated dosing, localized delivery, and broader therapeutic windows. Ongoing challenges include overcoming endosomal entrapment, ensuring sufficient transfection efficiency in post-mitotic cells, and reducing off-target accumulation in peripheral organs. Nevertheless, with continued refinement in surface chemistry, charge dynamics, and targeting strategies, non-viral nanocarriers are poised to become a central tool in next-generation CNS gene delivery.

References: Altogen.com Altogenlabs.com